Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication.

MLA

Buti, Sebastiano, et al. “Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication.” Journal of Immunotherapy (Hagerstown, Md. : 1997), vol. 46, no. 1, Jan. 2023, pp. 22–26. EBSCOhost, https://doi.org/10.1097/CJI.0000000000000446.

APA

Buti, S., Basso, U., Giannarelli, D., De Giorgi, U., Maruzzo, M., Iacovelli, R., Galli, L., Porta, C., Carrozza, F., Procopio, G., Fonarini, G., Lo Re, G., Santoni, M., Sabbatini, R., Cusmai, A., Zucali, P. A., Aschele, C., Baldini, E., Zafarana, E., … Bersanelli, M. (2023). Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication. Journal of Immunotherapy (Hagerstown, Md. : 1997), 46(1), 22–26. https://doi.org/10.1097/CJI.0000000000000446

Chicago

Buti, Sebastiano, Umberto Basso, Diana Giannarelli, Ugo De Giorgi, Marco Maruzzo, Roberto Iacovelli, Luca Galli, et al. 2023. “Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication.” Journal of Immunotherapy (Hagerstown, Md. : 1997) 46 (1): 22–26. doi:10.1097/CJI.0000000000000446.